ATE521701T1 - Verbesserte konstrukte zur expression lysosomaler polypeptide - Google Patents

Verbesserte konstrukte zur expression lysosomaler polypeptide

Info

Publication number
ATE521701T1
ATE521701T1 AT04704039T AT04704039T ATE521701T1 AT E521701 T1 ATE521701 T1 AT E521701T1 AT 04704039 T AT04704039 T AT 04704039T AT 04704039 T AT04704039 T AT 04704039T AT E521701 T1 ATE521701 T1 AT E521701T1
Authority
AT
Austria
Prior art keywords
gaa
lysosomal
utr
isolated nucleic
polypeptide
Prior art date
Application number
AT04704039T
Other languages
English (en)
Inventor
Dwight Koeberl
Baodong Sun
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of ATE521701T1 publication Critical patent/ATE521701T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT04704039T 2003-01-22 2004-01-21 Verbesserte konstrukte zur expression lysosomaler polypeptide ATE521701T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44178903P 2003-01-22 2003-01-22
PCT/US2004/001453 WO2004064750A2 (en) 2003-01-22 2004-01-21 Improved constructs for expressing lysosomal polypeptides

Publications (1)

Publication Number Publication Date
ATE521701T1 true ATE521701T1 (de) 2011-09-15

Family

ID=32771976

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04704039T ATE521701T1 (de) 2003-01-22 2004-01-21 Verbesserte konstrukte zur expression lysosomaler polypeptide

Country Status (7)

Country Link
US (3) US20040248262A1 (de)
EP (1) EP1587923B1 (de)
JP (1) JP5433133B2 (de)
AT (1) ATE521701T1 (de)
ES (1) ES2371913T3 (de)
PT (1) PT1587923E (de)
WO (1) WO2004064750A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1974752B1 (de) * 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subzelluläres Targeting von therapeutischen Proteinen
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8889127B2 (en) * 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
JP2009501784A (ja) * 2005-07-18 2009-01-22 プロタリクス リミテッド 生物学的に活性な高分子の粘膜投与または経腸投与
FR2889066B1 (fr) * 2005-07-28 2007-11-09 Centre Nat Rech Scient Procede d'immunisation genetique par electrotransfert contre une toxine et antiserum susceptible d'etre obtenu par ledit procede
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
US20120322861A1 (en) * 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
WO2009075815A1 (en) * 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
ES2629853T3 (es) * 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
WO2010080720A2 (en) 2009-01-12 2010-07-15 Nektar Therapeutics Conjugates of a lysosomal enzyme moiety and a water soluble polymer
EP2215981B1 (de) * 2009-02-04 2013-04-03 Stryker Leibinger GmbH & Co. KG Chirurgisches Elektrowerkzeug, Betriebsverfahren und Betätigungsbaugruppe hierfür
ES2398006T3 (es) * 2009-02-04 2013-03-13 Stryker Leibinger Gmbh & Co. Kg Herramienta quirúrgica eléctrica y conjunto de accionamiento para la misma
EP2475376B1 (de) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
UA115649C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс ідуронат-2-сульфатази
AU2011270670B2 (en) 2010-06-25 2017-01-12 Takeda Pharmaceutical Company Limited Methods and compositions for CNS delivery of arylsulfatase A
ES2896060T3 (es) 2010-06-25 2022-02-23 Shire Human Genetic Therapies Métodos y composiciones para la administración al SNC de arilsulfatasa A
CA2805413A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of heparan n-sulfatase
NZ702801A (en) 2010-06-25 2016-08-26 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
EP2588130B1 (de) 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Abgabe therapeutischer mittel in das zns
AU2010366066B2 (en) 2010-12-22 2016-01-14 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
RU2013151875A (ru) * 2011-04-22 2015-05-27 Джензим Корпорейшн Модифицированная кислая альфа глюкозидаза с ускоренным процессингом
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP3741384A1 (de) 2011-09-07 2020-11-25 Mount Sinai School Of Medicine Ceramidase und zelldifferenzierung
CN103958676A (zh) * 2011-10-12 2014-07-30 辛那杰瓦生物制药股份有限公司 重组人naglu蛋白质及其用途
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CN109529028A (zh) 2012-06-01 2019-03-29 西奈山伊坎医学院 在感染的治疗和预防中的神经酰胺水平
SMT202000445T1 (it) 2012-06-19 2020-09-10 Univ Florida Composizioni e metodi per trattare patologie
WO2014130723A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
WO2014160390A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
WO2016149508A1 (en) 2015-03-19 2016-09-22 Shire Human Genetic Therapies, Inc. Mrna therapy for pompe disease
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3293259A1 (de) 2016-09-12 2018-03-14 Genethon Saure alpha-glucosidase-varianten und verwendungen davon
PE20191203A1 (es) 2016-09-12 2019-09-10 Genethon Variantes de alfa-glucosidasa acida y usos de las mismas
EP3293203A1 (de) * 2016-09-12 2018-03-14 Genethon Saure alpha-glucosidase-varianten und verwendungen davon
EP3293260A1 (de) 2016-09-12 2018-03-14 Genethon Saure alpha-glucosidase-varianten und verwendungen davon
US11160493B2 (en) * 2017-03-03 2021-11-02 Musclesound, Inc. System and method for determining a subject's muscle fuel level, muscle fuel rating, and muscle energy status
ES3065816T3 (en) 2017-06-07 2026-05-08 Regeneron Pharma Compositions and methods for internalizing enzymes
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
JP7749322B2 (ja) 2018-04-30 2025-10-06 アミカス セラピューティックス インコーポレイテッド 遺伝子治療構築物及び使用方法
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
EA202190999A1 (ru) 2018-10-10 2021-10-15 Амикус Терапьютикс, Инк. Композиции на основе полипептидов, стабилизированных с помощью дисульфидной связи, и способы применения
JP2022507268A (ja) * 2018-11-13 2022-01-18 デノボ バイオファーマ エルエルシー 結合ドメインおよび分泌可能なペプチドの遺伝子を含む組換えベクター
EP3880830A4 (de) * 2018-11-16 2022-08-24 Asklepios Biopharmaceutical, Inc. Vektoren mit einer nukleinsäure codierend für lysosomale enzyme kondensiert an eine lysosomale targeting-sequenz
AU2019381776A1 (en) * 2018-11-16 2021-07-01 AskBio Inc. Therapeutic adeno-associated virus for treating Pompe disease
CA3134485A1 (en) * 2019-04-30 2020-11-05 James M. Wilson Compositions useful for treatment of pompe disease
AU2020338014A1 (en) * 2019-08-28 2022-03-03 University Of Florida Research Foundation, Incorporated Improved production of recombinant AAV using embryonated avian eggs
CN114555808A (zh) 2019-10-22 2022-05-27 吉尼松公司 嵌合多肽及其用途
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
PH12022551229A1 (en) * 2019-11-19 2023-07-31 Asklepios Biopharmaceutical Inc Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
PE20221266A1 (es) 2019-12-20 2022-08-16 Codexis Inc Variantes de alfa-glucosidasa acida disenadas por ingenieria
JP2023538002A (ja) * 2020-08-13 2023-09-06 エピバックス・インコーポレーテッド 制御性ｔ細胞エピトープ
CN117042723A (zh) * 2021-01-26 2023-11-10 西吉隆医疗股份有限公司 用于诱导抗原特异性免疫耐受的组合物、装置和方法
WO2022164928A2 (en) * 2021-01-26 2022-08-04 Sigilon Therapeutics, Inc. Compositions, devices and methods for treating immune-mediated inflammatory diseases
CN116964201A (zh) * 2021-02-05 2023-10-27 西吉隆医疗股份有限公司 用于治疗mps vi疾病的组合物、装置和方法
WO2023076972A1 (en) * 2021-10-27 2023-05-04 The University Of North Carolina At Chapel Hill Aav-idua vector for treatment of mps i
US20250213726A1 (en) * 2022-03-18 2025-07-03 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus using codon optimized nucleic acid encoding alpha-glucosidase (gaa) for treating pompe disease, with signal peptide modifications
WO2024131237A1 (en) * 2022-12-21 2024-06-27 Hwu Wuh Liang Recombinant viral vector, recombinant adeno-associated virus comprising the same, and uses thereof in treating sialidosis
IL327407A (en) * 2023-09-29 2026-05-01 The Board Of Regents Of The Univ Of Texas System Endogenous nucleus targeting signal peptides and their uses
AU2024359822A1 (en) * 2023-10-09 2026-04-30 The Board Of Regents Of The University Of Texas System Endogenous cell membrane targeting signal peptides and uses thereof
WO2025097038A1 (en) * 2023-11-03 2025-05-08 The Board Of Regents Of The University Of Texas System Endogenous cell junction targeting signal peptides and uses thereof
WO2025106882A1 (en) * 2023-11-15 2025-05-22 The Board Of Regents Of The University Of Texas System Endogenous cytoplasm targeting signal peptides and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4407956A (en) 1981-03-13 1983-10-04 The Regents Of The University Of California Cloned cauliflower mosaic virus DNA as a plant vehicle
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
DE3432718C1 (de) 1984-09-06 1986-05-22 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
JP2627899B2 (ja) 1987-08-19 1997-07-09 株式会社 ビタミン研究所 遺伝子封入リポソームの製法
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
WO1991003556A1 (en) * 1989-09-05 1991-03-21 Biotechnology Australia Pty Ltd Recombinant product
EP0452457B1 (de) 1989-11-03 1997-08-20 Vanderbilt University Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5225341A (en) 1990-07-19 1993-07-06 The Regents Of The University Of California Biologically safe plant transformation system using a ds transposon
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5339346A (en) 1993-05-20 1994-08-16 At&T Bell Laboratories Device fabrication entailing plasma-derived x-ray delineation
ATE272123T1 (de) 1993-11-09 2004-08-15 Ohio Med College Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5623054A (en) 1994-06-23 1997-04-22 The General Hospital Corporation Crucifer AFT proteins and uses thereof
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
CA2207927A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
PT1538202E (pt) * 1996-09-13 2014-04-22 Shire Human Genetic Therapies Produção de alga-galactosidase a humana
JP2001510457A (ja) 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製
EP0946723A1 (de) 1996-12-18 1999-10-06 Targeted Genetics Corporation Rekombinase-aktivierbare aav verpackungskassette zur herstellung von aav vektoren
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
EP1080218A1 (de) 1998-05-27 2001-03-07 University of Florida Methode zur darstellung von rekombinanten adeno-assoziierten virus zusammensetzungen mit hilfe von iodixanol gradienten
CA2340276A1 (en) * 1998-08-28 2000-03-09 Duke University Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
US6858425B1 (en) * 1998-12-04 2005-02-22 Genzyme Corporation Human acid alpha glucosidase gene and bovine alpha-S1 casein gene sequences
CA2353522A1 (en) * 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Treatment of pompe's disease
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
ATE323766T1 (de) 1999-02-12 2006-05-15 Amgen Inc Glykosylierte leptinzusammensetzungen und zugehörige verfahren
WO2001036603A2 (en) * 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
DK1782825T3 (da) * 2000-07-18 2014-11-03 Univ Duke Behandling af glycogenlagringssygdom type II
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1974752B1 (de) * 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subzelluläres Targeting von therapeutischen Proteinen
US6946126B2 (en) * 2001-06-04 2005-09-20 Duke University Replicating adenovirus vectors
US7071172B2 (en) * 2002-04-30 2006-07-04 The University Of North Carolina At Chapel Hill Secretion signal vectors
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins

Also Published As

Publication number Publication date
JP2006517404A (ja) 2006-07-27
WO2004064750A3 (en) 2004-11-11
ES2371913T3 (es) 2012-01-11
US20180371440A1 (en) 2018-12-27
PT1587923E (pt) 2011-12-07
WO2004064750A2 (en) 2004-08-05
US9873868B2 (en) 2018-01-23
US20040248262A1 (en) 2004-12-09
EP1587923A2 (de) 2005-10-26
JP5433133B2 (ja) 2014-03-05
EP1587923B1 (de) 2011-08-24
US20120276072A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
WO2004064750A3 (en) Improved constructs for expressing lysosomal polypeptides
ATE454455T1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
CY1112334T1 (el) Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων
Masuda et al. A novel plant ferritin subunit from soybean that is related to a mechanism in iron release
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
DK1623990T3 (da) Sammensætninger og fremgangsmåder til tumorbehandling
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
DK0941318T5 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
ATE478145T1 (de) Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
MXPA03010077A (es) Abonadora de siembra a voleo con deflector movible.
ATE397061T1 (de) Verfahren zur herstellung von proteinen
ATE444971T1 (de) Zusammensetzungen und verfahren für die tumor- behandlung
ATE448312T1 (de) Leitsequenzen zur verwendung bei der produktion von proteinen
WO2001087978A3 (en) Human abc transporter and its use
MXPA04004561A (es) Distribuidor de aire para sistema de biolixiviacion.
ES2264700T3 (es) Preparacion de una proteina recombinante en una celula huesped procariotica mediante el uso de un codon mejorado.
DE69838644D1 (de) Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
ATE452137T1 (de) Verfahren und konstrukte zur expression von clostripain mit hoher ausbeute
EP1281758A3 (de) Vier menschliche Zinc-Finger Proteine: MDZ3, MDZ4, MDZ7 und MDZ12
DE69031996D1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
ATE317896T1 (de) Polypeptide mit glucanotransferase aktivität und dafür kodierende nukleinsäuren
DE602004023927D1 (de) Ghrh zur verwendung bei der behandlung von chronischer niereninsuffizienz
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
DE60225046D1 (de) Produktion eukaryontischer proteine und nukleinsäuremoleküle in c. elegans
DE60011464D1 (de) Herstellung von heterloge proteine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties